Faeth Therapeutics, Inc expected to post a loss of $3.62 a share - Earnings Preview

Faeth Therapeutics

31/07/2026 14:43

Faeth Therapeutics, Inc FTH.OQ FTH.O is expected to  show no change in quarterly revenue when it reports  results on August 3 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for Faeth Therapeutics, Inc is for a loss of $3.62 per share. 
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Faeth Therapeutics, Inc is $55.00, about 90.8% above its last closing price of $28.82
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.62
-0.62
-28.79
Missed
-4,543.5
Dec. 31 2026
-4.81
-3.74
Beat
22.2
Sep. 30 2025
-4.11
-4.11
-3.62
Beat
11.9​
Jun. 30 2025
-5.53
-5.60
-3.91
Beat
30.2
​​Mar. 31 2025
-4.99
-4.47
-5.40
Missed
-20.9
Dec. 31 2024
-5.80
-5.53
-6.20
Missed
-12​
Sep. 30 2024
-6.19
-6.25
-5.80
Beat
7.2
Jun. 30 2024
-5.91
-5.77
-5.60
Beat
2.9
This summary was machine generated July 31 at 13:43 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)